Clinical Trials Browser

Neoplasm, Residual × dinutuximab × Clear all

NCT02169609 2024-04-22

Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

Phase 2 Completed

Neuroblastoma, Neoplasm, Residual